Mental Health Clinical Trials Market Research Reveals Strong 8.6% CAGR Outlook Through 2030

Exploring the future landscape of mental health clinical trials reveals promising growth fueled by technological advances and expanding research efforts. As innovation and investment accelerate in this field, the market is set to evolve significantly in the coming years. Below is an overview of the market size, key players, emerging trends, and the main segments shaping this dynamic industry.

Projected Growth and Market Size of Mental Health Clinical Trials
The mental health clinical trials market is anticipated to experience substantial expansion, reaching a valuation of $4.89 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 8.6% over the forecast period. Several factors are driving this upward trajectory, including the increasing use of digital mental health interventions, greater investments in personalized psychiatry research, and the broadening scope of global mental health trial networks. Additionally, enhanced regulatory backing for innovative trial designs and a rising reliance on data-driven outcome assessments are contributing to this progress. Notable emerging trends involve the adoption of decentralized clinical trial models, integration of digital therapeutics into trials, application of AI-driven patient recruitment tools, expansion of remote patient monitoring, and a heightened focus on generating real-world evidence.

The mental health clinical trials market size has grown strongly in recent years. It will grow from $3.23 billion in 2025 to $3.52 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increasing prevalence of mental health disorders, expansion of pharmaceutical research pipelines, growing awareness of mental health conditions, rising clinical research funding, increasing use of standardized diagnostic criteria.

Download a free sample of the mental health clinical trials market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27343&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Contributors in the Mental Health Clinical Trials Sector
A number of prominent companies are influential in the mental health clinical trials market, including Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials, Inc., Ergomed, Celerion Inc., Biotrial S.A.S., Lindus Health Ltd., Novotech Health Holdings Pte Ltd., and Precision for Medicine Inc.

In a notable collaboration in March 2025, Wysa, a US-based mental health technology firm, partnered with April Health Inc., a digital behavioral health company in the US, to embed Wysa's AI coach into primary care settings. This alliance aims to enhance access to mental health services, streamline support for patients, and improve outcomes through continuous, technology-enabled care.

View the full mental health clinical trials market report:
https://www.thebusinessresearchcompany.com/report/mental-health-clinical-trials-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Innovative Trends Emerging in Mental Health Clinical Trials
Leading companies in this market are increasingly emphasizing the development of innovative solutions such as software-enhanced drug therapies. These therapies combine conventional medications with clinically validated therapeutic software, designed to improve treatment effectiveness, tailor patient care, and support real-world therapeutic benefits.

For example, in October 2024, Click Therapeutics Inc., a US-based digital therapeutics firm, launched Click SE, a pioneering software-enhanced drug therapy offering. This product line integrates prescription software with pharmacotherapy to deliver supplementary clinical advantages and enable new endpoints in mental health clinical research. Click SE consists of regulated mobile and cloud applications built on Click's AI-enabled digital therapeutics platform. It delivers structured therapeutic programs, real-time symptom tracking, and medication-specific digital assistance intended to complement co-prescribed drugs. Its adaptive algorithms personalize content according to patient responses, accommodate pharmacologic dosing schedules, and provide built-in metrics for objective clinical trial endpoints. Applications include augmenting antipsychotics for negative symptoms, serving as adjunctive treatments in depression, and offering support for substance-use disorders.

Breakdown of Key Segments Driving Mental Health Clinical Trials Market
This market is segmented into several key categories:

1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Other Study Designs
3) By Disorder: Anxiety Disorders, Depression, Bipolar Affective Disorder, Dissociation and Dissociative Disorders, Schizophrenia, Other Disorders
4) By Sponsor: Pharmaceutical and Biopharmaceutical Companies, Government Agencies, Other Sponsors

Further subsegments within each phase include:

- Phase I: Single Ascending Dose, Multiple Ascending Dose, First In Human, Pharmacokinetics Studies
- Phase II: Dose Ranging Studies, Proof of Concept Studies, Randomized Controlled Trials, Open Label Studies
- Phase III: Large Scale Randomized Trials, Multicenter Studies, Comparative Effectiveness Trials, Double Blind Studies
- Phase IV: Post Marketing Surveillance, Long Term Safety Studies, Real World Evidence Studies, Pharmacovigilance Studies

This detailed segmentation reflects the complexity and diversity of mental health clinical trials, highlighting the varied methodologies and therapeutic focuses that collectively drive market expansion.

New additions to our 2026 reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.